Treatment Database

A selective HCN4 channel blocker that reduces heart rate by blocking the funny current of the sinus node. A randomized double-blind placebo-controlled crossover trial (Taub et al. 2021, n=22 hyperadrenergic POTS) demonstrated significant reductions in heart rate and improvements in quality of life. A prospective cohort study of 55 COVID-associated POTS patients (Abdelnabi et al. 2023) found 78% reported symptom improvement within 7 days, with significant heart rate reductions and improved HRV. A 2026 placebo-controlled crossover trial (Uppal et al., JACC; n=28) found that 4 weeks of ivabradine lowered peak heart rate on tilt from 118 to 99 beats/min, similar to propranolol, with a slightly larger rise in blood pressure. The largest trial to date, RECOVER-AUTONOMIC (NCT06305780), randomized 181 people with Long COVID POTS to 3 months of ivabradine or placebo; it did not select or stratify participants by POTS subtype. Results presented at ACC.26 showed it missed its primary endpoint: ivabradine blunted the standing heart rate increase versus placebo (adjusted difference –3.95 bpm, p=0.007) but did not improve orthostatic intolerance (OHQ composite –0.14, p=0.63), nor MAPS symptom score, COMPASS-31, 6-minute walk distance, or PROMIS physical function. A prespecified factorial analysis (interaction p=0.004) found benefit when ivabradine was paired with coordinated care (salt, fluids, compression garments, activity guidance, and weekly care-coordinator calls; OHQ –1.03 vs placebo plus coordinated care) but not with usual care. Full results are not yet published in a journal.